Population pharmacokinetics research of clozapine in Chinese schizophrenic patients

Yaoxue Xuebao

Volumn 44, Issue 7, 2009, Pages 785-792

  Qiu, Xue Wen ^a,b   Fu, Pei Xin ^c   Wang, Chuan Yue ^c   Liu, Min ^c   Zhou, Tian Yan ^a,b   Lu, Wei ^a,b  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Clozapine; Genetic polymorphism; Population pharmacokinetics; Schizophrenia

Indexed keywords

CLOZAPINE; CYTOCHROME P450 1A2;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHINESE; DEMOGRAPHY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PHARMACOKINETICS; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CLOZAPINE; FEMALE; GENETICS, POPULATION; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; SCHIZOPHRENIA; YOUNG ADULT;

EID: 70049117721     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Freedman R. Drug therapy: schizophrenia [J]. N Engl J Med, 2003, 49: 1738-1749.
2. He B, Ding YQ, Wang CY. Review of the literature on clozapine-induced leukopenia and agranulocytosis in China [J]. Eval Anal Drug Use Hosp China, 2003, 3: 307-311.
3. Si TM, Yu X. Antipsychotic drug patterns of schizophrenia in China: a cross-sectioned study [J]. Chin J Psychiatry, 2004, 37: 152-155.
4. Pirmohamed M, Williams D, Madden S. Metabolism and bioactivation of clozapine by human liver in vitro [J]. J Pharmacol Exp Ther, 1995, 272: 984-990.
5. Eiermann B, Engel G, Johansson I. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine [J]. Br J Clin Pharmacol, 1997, 44: 439-446. (Pubitemid 27485474)
6. Dailly E, Urien S, Chanut E, et al. Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter- and intraindividual variations of clozapine clearance [J]. Prog Neuropsychopharmacol Biol Psychiatry, 2002, 26: 699-703. (Pubitemid 34615975)
7. Ozdemir V, Kalow W, Posner P, et al. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration patients with schizophrenia [J]. J Clin Psychopharmacol, 2001, 21: 398-407. (Pubitemid 32673029)
8. Zhai YM, Li WB, Wang CY, et al. RP-HPLC determination of clozapine and its two major metabolites in whole blood, plasma and red blood cells [J]. Chin New Drugs J, 2002, 11: 141-144.
9. Haring C, Meise U, Humpel C, et al. Dose related plasma levels of clozapine: influence of smoking behaviour, sex and age [J]. Psychopharmacology (Berl), 1989, 99: S38-40. (Pubitemid 19244137)
10. Ishibashi T, Yano Y, Oguma T. Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients [J]. Br J Clin Pharmacol, 2003, 56: 205-213. (Pubitemid 36981436)
11. Blanco SB, Otero MJ, Santos BD, et al. Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data [J]. Biopharm Drug Dispos, 1999, 20: 233-240.
12. Guitton C, Kinowski JM, Abbar M, et al. Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia [J]. J Clin Pharmacol, 1999, 39: 721-728.
13. Tassaneeyakul W, Kittiwattanagul K, Vannaprasaht S, et al. Steady-state bioequivalence study of clozapine tablet in schizophrenic patients [J]. J Pharm Pharm Sci, 2005, 8: 47-53. (Pubitemid 41528869)
14. Teng JR, Zhang SQ, Chen YM, et al. Relationship between metabolism of clozapine in the body and polymorphisms of the locus cytochrome P450 1A2-2964 [J]. Chin J Clin Pharm Ther, 2003, 8: 176-179.
15. van der Weidea J, Steijnsa LSW, van Weelden MJM. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement [J]. Pharmacogenetics, 2003, 13: 169-172.
16. Olesen OV, Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations [J]. J Clin Pharmacol, 2001, 41: 823-832. (Pubitemid 32692092)
17. Wang CY, Ouyang DS, Zhou HH, et al. Correlation between a caffeine test and clozapine metabolism in vivo [J]. Chin J Clin Pharm, 2000, 33: 16-19.
18. Li F, Jiang KD, Jiang SD, et al. Novel mutation of the cytochrome P450 1A2 gene associated with the clinical response to clozapine in Chinese schizophrenic patients [J]. Shanghai Arch Psychiatry, 2004, 16: 136-139.
19. Chen YM, Wang G, Zhang SQ, et al. Relationship between the metabolism of clozapine in patients with schizophrenia and polymorphism of the Loci-2964 and 734 in cytochrome P (450) 1A2 [J]. Her Med, 2005, 24: 870-874.
20. Sachse C, Brockmoller J, Bauer S, et al. Functional significance of a C/A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine [J]. Br J Clin Pharmacol, 1999, 47: 445-449. (Pubitemid 29161279)